nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—hematologic cancer	0.338	0.81	CbGaD
Naltrexone—ABCB1—hematologic cancer	0.079	0.19	CbGaD
Naltrexone—UGT1A1—Nilotinib—hematologic cancer	0.0546	0.176	CbGbCtD
Naltrexone—UGT1A1—Irinotecan—hematologic cancer	0.0375	0.121	CbGbCtD
Naltrexone—UGT1A1—Etoposide—hematologic cancer	0.03	0.0968	CbGbCtD
Naltrexone—ABCB1—Lenalidomide—hematologic cancer	0.0265	0.0855	CbGbCtD
Naltrexone—ABCB1—Daunorubicin—hematologic cancer	0.0155	0.0501	CbGbCtD
Naltrexone—ABCB1—Alitretinoin—hematologic cancer	0.0152	0.0491	CbGbCtD
Naltrexone—ABCB1—Imatinib—hematologic cancer	0.0119	0.0384	CbGbCtD
Naltrexone—ABCB1—Nilotinib—hematologic cancer	0.0108	0.0349	CbGbCtD
Naltrexone—ABCB1—Vinorelbine—hematologic cancer	0.0107	0.0346	CbGbCtD
Naltrexone—ABCB1—Dasatinib—hematologic cancer	0.00956	0.0308	CbGbCtD
Naltrexone—ABCB1—Mitoxantrone—hematologic cancer	0.00945	0.0304	CbGbCtD
Naltrexone—ABCB1—Betamethasone—hematologic cancer	0.00842	0.0271	CbGbCtD
Naltrexone—ABCB1—Gemcitabine—hematologic cancer	0.00834	0.0269	CbGbCtD
Naltrexone—ABCB1—Prednisolone—hematologic cancer	0.00831	0.0268	CbGbCtD
Naltrexone—ABCB1—Prednisone—hematologic cancer	0.00785	0.0253	CbGbCtD
Naltrexone—ABCB1—Irinotecan—hematologic cancer	0.00744	0.024	CbGbCtD
Naltrexone—ABCB1—Vinblastine—hematologic cancer	0.00661	0.0213	CbGbCtD
Naltrexone—ABCB1—Vincristine—hematologic cancer	0.0065	0.021	CbGbCtD
Naltrexone—ABCB1—Cisplatin—hematologic cancer	0.00606	0.0195	CbGbCtD
Naltrexone—ABCB1—Etoposide—hematologic cancer	0.00596	0.0192	CbGbCtD
Naltrexone—ABCB1—Dexamethasone—hematologic cancer	0.0049	0.0158	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—hematologic cancer	0.00406	0.0131	CbGbCtD
Naltrexone—ABCB1—Methotrexate—hematologic cancer	0.00394	0.0127	CbGbCtD
Naltrexone—Naloxone—CREB1—hematologic cancer	0.00121	0.496	CrCbGaD
Naltrexone—Morphine—UGT1A1—hematologic cancer	0.00036	0.148	CrCbGaD
Naltrexone—Buprenorphine—ABCG2—hematologic cancer	0.000242	0.0992	CrCbGaD
Naltrexone—Naloxone—ESR1—hematologic cancer	0.000235	0.0965	CrCbGaD
Naltrexone—Naloxone—ALB—hematologic cancer	0.000105	0.043	CrCbGaD
Naltrexone—Buprenorphine—ABCB1—hematologic cancer	0.000101	0.0413	CrCbGaD
Naltrexone—Naloxone—ABCB1—hematologic cancer	9.98e-05	0.041	CrCbGaD
Naltrexone—Morphine—ABCB1—hematologic cancer	8.42e-05	0.0346	CrCbGaD
Naltrexone—Nervous system disorder—Prednisone—hematologic cancer	1.78e-05	8.21e-05	CcSEcCtD
Naltrexone—Tachycardia—Prednisone—hematologic cancer	1.77e-05	8.17e-05	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—hematologic cancer	1.76e-05	8.14e-05	CcSEcCtD
Naltrexone—Skin disorder—Prednisone—hematologic cancer	1.76e-05	8.13e-05	CcSEcCtD
Naltrexone—Nausea—Gemcitabine—hematologic cancer	1.76e-05	8.12e-05	CcSEcCtD
Naltrexone—Vomiting—Cisplatin—hematologic cancer	1.76e-05	8.1e-05	CcSEcCtD
Naltrexone—Hyperhidrosis—Prednisone—hematologic cancer	1.75e-05	8.09e-05	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—hematologic cancer	1.75e-05	8.08e-05	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—hematologic cancer	1.75e-05	8.07e-05	CcSEcCtD
Naltrexone—Rash—Cisplatin—hematologic cancer	1.74e-05	8.04e-05	CcSEcCtD
Naltrexone—Dermatitis—Cisplatin—hematologic cancer	1.74e-05	8.03e-05	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—hematologic cancer	1.74e-05	8.02e-05	CcSEcCtD
Naltrexone—Diarrhoea—Etoposide—hematologic cancer	1.73e-05	7.99e-05	CcSEcCtD
Naltrexone—Anorexia—Prednisone—hematologic cancer	1.73e-05	7.98e-05	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—hematologic cancer	1.73e-05	7.97e-05	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—hematologic cancer	1.72e-05	7.95e-05	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—hematologic cancer	1.72e-05	7.95e-05	CcSEcCtD
Naltrexone—Feeling abnormal—Dexamethasone—hematologic cancer	1.72e-05	7.92e-05	CcSEcCtD
Naltrexone—Feeling abnormal—Betamethasone—hematologic cancer	1.72e-05	7.92e-05	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—hematologic cancer	1.71e-05	7.91e-05	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—hematologic cancer	1.71e-05	7.9e-05	CcSEcCtD
Naltrexone—Tension—Epirubicin—hematologic cancer	1.71e-05	7.87e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.7e-05	7.86e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Betamethasone—hematologic cancer	1.7e-05	7.86e-05	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—hematologic cancer	1.7e-05	7.85e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Triamcinolone—hematologic cancer	1.69e-05	7.8e-05	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—hematologic cancer	1.69e-05	7.79e-05	CcSEcCtD
Naltrexone—Back pain—Epirubicin—hematologic cancer	1.68e-05	7.76e-05	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—hematologic cancer	1.68e-05	7.73e-05	CcSEcCtD
Naltrexone—Malaise—Methotrexate—hematologic cancer	1.67e-05	7.73e-05	CcSEcCtD
Naltrexone—Dizziness—Etoposide—hematologic cancer	1.67e-05	7.72e-05	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—hematologic cancer	1.67e-05	7.71e-05	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—hematologic cancer	1.67e-05	7.7e-05	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—hematologic cancer	1.66e-05	7.68e-05	CcSEcCtD
Naltrexone—Chills—Doxorubicin—hematologic cancer	1.66e-05	7.65e-05	CcSEcCtD
Naltrexone—Urticaria—Betamethasone—hematologic cancer	1.65e-05	7.63e-05	CcSEcCtD
Naltrexone—Urticaria—Dexamethasone—hematologic cancer	1.65e-05	7.63e-05	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.65e-05	7.62e-05	CcSEcCtD
Naltrexone—Dizziness—Prednisolone—hematologic cancer	1.65e-05	7.61e-05	CcSEcCtD
Naltrexone—Asthenia—Triamcinolone—hematologic cancer	1.65e-05	7.6e-05	CcSEcCtD
Naltrexone—Body temperature increased—Dexamethasone—hematologic cancer	1.65e-05	7.6e-05	CcSEcCtD
Naltrexone—Abdominal pain—Betamethasone—hematologic cancer	1.65e-05	7.6e-05	CcSEcCtD
Naltrexone—Abdominal pain—Dexamethasone—hematologic cancer	1.65e-05	7.6e-05	CcSEcCtD
Naltrexone—Body temperature increased—Betamethasone—hematologic cancer	1.65e-05	7.6e-05	CcSEcCtD
Naltrexone—Nausea—Cisplatin—hematologic cancer	1.64e-05	7.57e-05	CcSEcCtD
Naltrexone—Insomnia—Prednisone—hematologic cancer	1.64e-05	7.57e-05	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—hematologic cancer	1.64e-05	7.56e-05	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—hematologic cancer	1.63e-05	7.53e-05	CcSEcCtD
Naltrexone—Paraesthesia—Prednisone—hematologic cancer	1.63e-05	7.51e-05	CcSEcCtD
Naltrexone—Pruritus—Triamcinolone—hematologic cancer	1.62e-05	7.49e-05	CcSEcCtD
Naltrexone—Cough—Methotrexate—hematologic cancer	1.62e-05	7.48e-05	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—hematologic cancer	1.62e-05	7.47e-05	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—hematologic cancer	1.61e-05	7.44e-05	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—hematologic cancer	1.61e-05	7.42e-05	CcSEcCtD
Naltrexone—Vomiting—Etoposide—hematologic cancer	1.61e-05	7.42e-05	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—hematologic cancer	1.61e-05	7.42e-05	CcSEcCtD
Naltrexone—Agitation—Epirubicin—hematologic cancer	1.6e-05	7.37e-05	CcSEcCtD
Naltrexone—Rash—Etoposide—hematologic cancer	1.6e-05	7.36e-05	CcSEcCtD
Naltrexone—Dermatitis—Etoposide—hematologic cancer	1.59e-05	7.35e-05	CcSEcCtD
Naltrexone—Headache—Etoposide—hematologic cancer	1.58e-05	7.31e-05	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—hematologic cancer	1.58e-05	7.31e-05	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—hematologic cancer	1.58e-05	7.3e-05	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—hematologic cancer	1.58e-05	7.3e-05	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—hematologic cancer	1.58e-05	7.3e-05	CcSEcCtD
Naltrexone—Tension—Doxorubicin—hematologic cancer	1.58e-05	7.28e-05	CcSEcCtD
Naltrexone—Decreased appetite—Prednisone—hematologic cancer	1.58e-05	7.27e-05	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—hematologic cancer	1.57e-05	7.27e-05	CcSEcCtD
Naltrexone—Rash—Prednisolone—hematologic cancer	1.57e-05	7.26e-05	CcSEcCtD
Naltrexone—Dermatitis—Prednisolone—hematologic cancer	1.57e-05	7.25e-05	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.57e-05	7.24e-05	CcSEcCtD
Naltrexone—Malaise—Epirubicin—hematologic cancer	1.57e-05	7.23e-05	CcSEcCtD
Naltrexone—Fatigue—Prednisone—hematologic cancer	1.56e-05	7.21e-05	CcSEcCtD
Naltrexone—Headache—Prednisolone—hematologic cancer	1.56e-05	7.21e-05	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—hematologic cancer	1.56e-05	7.21e-05	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—hematologic cancer	1.56e-05	7.21e-05	CcSEcCtD
Naltrexone—Syncope—Epirubicin—hematologic cancer	1.56e-05	7.19e-05	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—hematologic cancer	1.56e-05	7.18e-05	CcSEcCtD
Naltrexone—Constipation—Prednisone—hematologic cancer	1.55e-05	7.16e-05	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—hematologic cancer	1.55e-05	7.13e-05	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—hematologic cancer	1.54e-05	7.09e-05	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—hematologic cancer	1.53e-05	7.05e-05	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—hematologic cancer	1.53e-05	7.05e-05	CcSEcCtD
Naltrexone—Dizziness—Triamcinolone—hematologic cancer	1.52e-05	7e-05	CcSEcCtD
Naltrexone—Cough—Epirubicin—hematologic cancer	1.52e-05	7e-05	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—hematologic cancer	1.52e-05	6.99e-05	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—hematologic cancer	1.52e-05	6.99e-05	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—hematologic cancer	1.51e-05	6.95e-05	CcSEcCtD
Naltrexone—Infection—Methotrexate—hematologic cancer	1.51e-05	6.95e-05	CcSEcCtD
Naltrexone—Nausea—Etoposide—hematologic cancer	1.5e-05	6.93e-05	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—hematologic cancer	1.5e-05	6.92e-05	CcSEcCtD
Naltrexone—Feeling abnormal—Prednisone—hematologic cancer	1.49e-05	6.9e-05	CcSEcCtD
Naltrexone—Asthenia—Dexamethasone—hematologic cancer	1.49e-05	6.89e-05	CcSEcCtD
Naltrexone—Asthenia—Betamethasone—hematologic cancer	1.49e-05	6.89e-05	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—hematologic cancer	1.49e-05	6.88e-05	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—hematologic cancer	1.49e-05	6.86e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Prednisone—hematologic cancer	1.48e-05	6.84e-05	CcSEcCtD
Naltrexone—Nausea—Prednisolone—hematologic cancer	1.48e-05	6.84e-05	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—hematologic cancer	1.48e-05	6.83e-05	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—hematologic cancer	1.48e-05	6.83e-05	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—hematologic cancer	1.48e-05	6.83e-05	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—hematologic cancer	1.48e-05	6.82e-05	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—hematologic cancer	1.47e-05	6.8e-05	CcSEcCtD
Naltrexone—Pruritus—Betamethasone—hematologic cancer	1.47e-05	6.8e-05	CcSEcCtD
Naltrexone—Pruritus—Dexamethasone—hematologic cancer	1.47e-05	6.8e-05	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—hematologic cancer	1.47e-05	6.79e-05	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.47e-05	6.78e-05	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—hematologic cancer	1.46e-05	6.76e-05	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—hematologic cancer	1.46e-05	6.75e-05	CcSEcCtD
Naltrexone—Vomiting—Triamcinolone—hematologic cancer	1.46e-05	6.73e-05	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—hematologic cancer	1.45e-05	6.69e-05	CcSEcCtD
Naltrexone—Rash—Triamcinolone—hematologic cancer	1.45e-05	6.68e-05	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—hematologic cancer	1.45e-05	6.68e-05	CcSEcCtD
Naltrexone—Dermatitis—Triamcinolone—hematologic cancer	1.45e-05	6.67e-05	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—hematologic cancer	1.44e-05	6.67e-05	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—hematologic cancer	1.44e-05	6.65e-05	CcSEcCtD
Naltrexone—Urticaria—Prednisone—hematologic cancer	1.44e-05	6.65e-05	CcSEcCtD
Naltrexone—Headache—Triamcinolone—hematologic cancer	1.44e-05	6.63e-05	CcSEcCtD
Naltrexone—Body temperature increased—Prednisone—hematologic cancer	1.43e-05	6.61e-05	CcSEcCtD
Naltrexone—Abdominal pain—Prednisone—hematologic cancer	1.43e-05	6.61e-05	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—hematologic cancer	1.43e-05	6.6e-05	CcSEcCtD
Naltrexone—Diarrhoea—Dexamethasone—hematologic cancer	1.42e-05	6.57e-05	CcSEcCtD
Naltrexone—Diarrhoea—Betamethasone—hematologic cancer	1.42e-05	6.57e-05	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—hematologic cancer	1.42e-05	6.56e-05	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—hematologic cancer	1.42e-05	6.54e-05	CcSEcCtD
Naltrexone—Oedema—Epirubicin—hematologic cancer	1.42e-05	6.54e-05	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—hematologic cancer	1.41e-05	6.52e-05	CcSEcCtD
Naltrexone—Infection—Epirubicin—hematologic cancer	1.41e-05	6.5e-05	CcSEcCtD
Naltrexone—Cough—Doxorubicin—hematologic cancer	1.4e-05	6.47e-05	CcSEcCtD
Naltrexone—Shock—Epirubicin—hematologic cancer	1.4e-05	6.44e-05	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—hematologic cancer	1.39e-05	6.43e-05	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—hematologic cancer	1.39e-05	6.42e-05	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—hematologic cancer	1.39e-05	6.41e-05	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—hematologic cancer	1.38e-05	6.39e-05	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.38e-05	6.37e-05	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—hematologic cancer	1.38e-05	6.36e-05	CcSEcCtD
Naltrexone—Dizziness—Dexamethasone—hematologic cancer	1.38e-05	6.35e-05	CcSEcCtD
Naltrexone—Dizziness—Betamethasone—hematologic cancer	1.38e-05	6.35e-05	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—hematologic cancer	1.37e-05	6.33e-05	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—hematologic cancer	1.37e-05	6.33e-05	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—hematologic cancer	1.37e-05	6.32e-05	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—hematologic cancer	1.37e-05	6.32e-05	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—hematologic cancer	1.37e-05	6.32e-05	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—hematologic cancer	1.36e-05	6.29e-05	CcSEcCtD
Naltrexone—Nausea—Triamcinolone—hematologic cancer	1.36e-05	6.29e-05	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—hematologic cancer	1.36e-05	6.28e-05	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.36e-05	6.27e-05	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—hematologic cancer	1.35e-05	6.24e-05	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—hematologic cancer	1.35e-05	6.24e-05	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—hematologic cancer	1.35e-05	6.23e-05	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—hematologic cancer	1.35e-05	6.22e-05	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—hematologic cancer	1.34e-05	6.18e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Prednisone—hematologic cancer	1.34e-05	6.17e-05	CcSEcCtD
Naltrexone—Vomiting—Betamethasone—hematologic cancer	1.32e-05	6.11e-05	CcSEcCtD
Naltrexone—Vomiting—Dexamethasone—hematologic cancer	1.32e-05	6.11e-05	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—hematologic cancer	1.32e-05	6.11e-05	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—hematologic cancer	1.32e-05	6.08e-05	CcSEcCtD
Naltrexone—Rash—Dexamethasone—hematologic cancer	1.31e-05	6.06e-05	CcSEcCtD
Naltrexone—Rash—Betamethasone—hematologic cancer	1.31e-05	6.06e-05	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—hematologic cancer	1.31e-05	6.06e-05	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—hematologic cancer	1.31e-05	6.06e-05	CcSEcCtD
Naltrexone—Dermatitis—Betamethasone—hematologic cancer	1.31e-05	6.05e-05	CcSEcCtD
Naltrexone—Dermatitis—Dexamethasone—hematologic cancer	1.31e-05	6.05e-05	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.31e-05	6.04e-05	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—hematologic cancer	1.31e-05	6.03e-05	CcSEcCtD
Naltrexone—Headache—Betamethasone—hematologic cancer	1.3e-05	6.02e-05	CcSEcCtD
Naltrexone—Headache—Dexamethasone—hematologic cancer	1.3e-05	6.02e-05	CcSEcCtD
Naltrexone—Infection—Doxorubicin—hematologic cancer	1.3e-05	6.02e-05	CcSEcCtD
Naltrexone—Asthenia—Prednisone—hematologic cancer	1.3e-05	6e-05	CcSEcCtD
Naltrexone—Pain—Methotrexate—hematologic cancer	1.3e-05	5.98e-05	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.29e-05	5.96e-05	CcSEcCtD
Naltrexone—Shock—Doxorubicin—hematologic cancer	1.29e-05	5.96e-05	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—hematologic cancer	1.29e-05	5.94e-05	CcSEcCtD
Naltrexone—Pruritus—Prednisone—hematologic cancer	1.28e-05	5.92e-05	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—hematologic cancer	1.28e-05	5.92e-05	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—hematologic cancer	1.28e-05	5.91e-05	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—hematologic cancer	1.27e-05	5.88e-05	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—hematologic cancer	1.27e-05	5.88e-05	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—hematologic cancer	1.27e-05	5.85e-05	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—hematologic cancer	1.26e-05	5.83e-05	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—hematologic cancer	1.26e-05	5.82e-05	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—hematologic cancer	1.25e-05	5.77e-05	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—hematologic cancer	1.25e-05	5.76e-05	CcSEcCtD
Naltrexone—Diarrhoea—Prednisone—hematologic cancer	1.24e-05	5.73e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—hematologic cancer	1.24e-05	5.72e-05	CcSEcCtD
Naltrexone—Nausea—Dexamethasone—hematologic cancer	1.24e-05	5.71e-05	CcSEcCtD
Naltrexone—Nausea—Betamethasone—hematologic cancer	1.24e-05	5.71e-05	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—hematologic cancer	1.23e-05	5.69e-05	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.22e-05	5.65e-05	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—hematologic cancer	1.22e-05	5.64e-05	CcSEcCtD
Naltrexone—Pain—Epirubicin—hematologic cancer	1.21e-05	5.6e-05	CcSEcCtD
Naltrexone—Constipation—Epirubicin—hematologic cancer	1.21e-05	5.6e-05	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—hematologic cancer	1.2e-05	5.56e-05	CcSEcCtD
Naltrexone—Dizziness—Prednisone—hematologic cancer	1.2e-05	5.53e-05	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—hematologic cancer	1.2e-05	5.53e-05	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—hematologic cancer	1.2e-05	5.53e-05	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.2e-05	5.52e-05	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—hematologic cancer	1.19e-05	5.48e-05	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—hematologic cancer	1.18e-05	5.44e-05	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—hematologic cancer	1.17e-05	5.4e-05	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—hematologic cancer	1.17e-05	5.39e-05	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—hematologic cancer	1.17e-05	5.38e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—hematologic cancer	1.16e-05	5.35e-05	CcSEcCtD
Naltrexone—Vomiting—Prednisone—hematologic cancer	1.15e-05	5.32e-05	CcSEcCtD
Naltrexone—Rash—Prednisone—hematologic cancer	1.14e-05	5.28e-05	CcSEcCtD
Naltrexone—Dermatitis—Prednisone—hematologic cancer	1.14e-05	5.27e-05	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—hematologic cancer	1.14e-05	5.26e-05	CcSEcCtD
Naltrexone—Headache—Prednisone—hematologic cancer	1.14e-05	5.24e-05	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.13e-05	5.23e-05	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—hematologic cancer	1.13e-05	5.22e-05	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—hematologic cancer	1.13e-05	5.2e-05	CcSEcCtD
Naltrexone—Pain—Doxorubicin—hematologic cancer	1.12e-05	5.18e-05	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—hematologic cancer	1.12e-05	5.18e-05	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—hematologic cancer	1.12e-05	5.17e-05	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—hematologic cancer	1.12e-05	5.17e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—hematologic cancer	1.12e-05	5.15e-05	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—hematologic cancer	1.09e-05	5.02e-05	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—hematologic cancer	1.08e-05	4.99e-05	CcSEcCtD
Naltrexone—Nausea—Prednisone—hematologic cancer	1.08e-05	4.97e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.07e-05	4.95e-05	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—hematologic cancer	1.07e-05	4.95e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—hematologic cancer	1.04e-05	4.82e-05	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—hematologic cancer	1.04e-05	4.81e-05	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—hematologic cancer	1.04e-05	4.79e-05	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—hematologic cancer	1.04e-05	4.79e-05	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—hematologic cancer	1.04e-05	4.78e-05	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—hematologic cancer	1.02e-05	4.7e-05	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—hematologic cancer	1e-05	4.63e-05	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—hematologic cancer	1e-05	4.62e-05	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—hematologic cancer	9.7e-06	4.48e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—hematologic cancer	9.67e-06	4.46e-05	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—hematologic cancer	9.64e-06	4.45e-05	CcSEcCtD
Naltrexone—Rash—Methotrexate—hematologic cancer	9.55e-06	4.41e-05	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—hematologic cancer	9.55e-06	4.41e-05	CcSEcCtD
Naltrexone—Headache—Methotrexate—hematologic cancer	9.49e-06	4.38e-05	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—hematologic cancer	9.41e-06	4.34e-05	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—hematologic cancer	9.38e-06	4.33e-05	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—hematologic cancer	9.28e-06	4.28e-05	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—hematologic cancer	9.02e-06	4.16e-05	CcSEcCtD
Naltrexone—Nausea—Methotrexate—hematologic cancer	9e-06	4.15e-05	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—hematologic cancer	8.98e-06	4.14e-05	CcSEcCtD
Naltrexone—Rash—Epirubicin—hematologic cancer	8.94e-06	4.13e-05	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—hematologic cancer	8.93e-06	4.12e-05	CcSEcCtD
Naltrexone—Headache—Epirubicin—hematologic cancer	8.88e-06	4.1e-05	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—hematologic cancer	8.68e-06	4e-05	CcSEcCtD
Naltrexone—Nausea—Epirubicin—hematologic cancer	8.42e-06	3.89e-05	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—hematologic cancer	8.34e-06	3.85e-05	CcSEcCtD
Naltrexone—Rash—Doxorubicin—hematologic cancer	8.27e-06	3.82e-05	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—hematologic cancer	8.27e-06	3.81e-05	CcSEcCtD
Naltrexone—Headache—Doxorubicin—hematologic cancer	8.22e-06	3.79e-05	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—TSC2—hematologic cancer	8.1e-06	0.00015	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDGFRA—hematologic cancer	8.09e-06	0.00015	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JAK1—hematologic cancer	8.06e-06	0.000149	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCG—hematologic cancer	8.06e-06	0.000149	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—JAK2—hematologic cancer	7.97e-06	0.000147	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAP2K1—hematologic cancer	7.94e-06	0.000147	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SPHK1—hematologic cancer	7.93e-06	0.000147	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GRB2—hematologic cancer	7.9e-06	0.000146	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CD—hematologic cancer	7.89e-06	0.000146	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFA—hematologic cancer	7.88e-06	0.000146	CbGpPWpGaD
Naltrexone—Nausea—Doxorubicin—hematologic cancer	7.79e-06	3.6e-05	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—FGFR3—hematologic cancer	7.79e-06	0.000144	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KITLG—hematologic cancer	7.77e-06	0.000144	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—hematologic cancer	7.71e-06	0.000143	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK14—hematologic cancer	7.71e-06	0.000143	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—UGT1A1—hematologic cancer	7.62e-06	0.000141	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT5A—hematologic cancer	7.59e-06	0.00014	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CB—hematologic cancer	7.57e-06	0.00014	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—hematologic cancer	7.56e-06	0.00014	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2RA—hematologic cancer	7.53e-06	0.000139	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN2B—hematologic cancer	7.52e-06	0.000139	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FN1—hematologic cancer	7.47e-06	0.000138	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—hematologic cancer	7.47e-06	0.000138	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	7.47e-06	0.000138	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3R1—hematologic cancer	7.45e-06	0.000138	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TERT—hematologic cancer	7.44e-06	0.000138	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CRABP1—hematologic cancer	7.41e-06	0.000137	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC22A1—hematologic cancer	7.41e-06	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BAD—hematologic cancer	7.38e-06	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFKBIA—hematologic cancer	7.38e-06	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH1—hematologic cancer	7.31e-06	0.000135	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD86—hematologic cancer	7.28e-06	0.000135	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDGFB—hematologic cancer	7.26e-06	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—JAK2—hematologic cancer	7.24e-06	0.000134	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALOX5—hematologic cancer	7.23e-06	0.000134	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	7.22e-06	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HES1—hematologic cancer	7.18e-06	0.000133	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CD80—hematologic cancer	7.16e-06	0.000132	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—hematologic cancer	7.15e-06	0.000132	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KIT—hematologic cancer	7.15e-06	0.000132	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—NRAS—hematologic cancer	7.15e-06	0.000132	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NCOR1—hematologic cancer	7.14e-06	0.000132	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TSC2—hematologic cancer	7.1e-06	0.000131	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF1—hematologic cancer	7.06e-06	0.00013	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CSF2—hematologic cancer	7.06e-06	0.00013	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTPN11—hematologic cancer	7.03e-06	0.00013	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NUP98—hematologic cancer	7e-06	0.000129	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FOXO1—hematologic cancer	6.95e-06	0.000129	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—hematologic cancer	6.95e-06	0.000129	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFRB—hematologic cancer	6.94e-06	0.000128	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CB—hematologic cancer	6.87e-06	0.000127	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK3—hematologic cancer	6.85e-06	0.000127	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFRA—hematologic cancer	6.83e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGFR3—hematologic cancer	6.83e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAK1—hematologic cancer	6.81e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCG—hematologic cancer	6.81e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CREB1—hematologic cancer	6.81e-06	0.000126	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADCY7—hematologic cancer	6.79e-06	0.000126	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA3—hematologic cancer	6.79e-06	0.000126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK14—hematologic cancer	6.76e-06	0.000125	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NUP214—hematologic cancer	6.75e-06	0.000125	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BRAF—hematologic cancer	6.72e-06	0.000124	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL2—hematologic cancer	6.66e-06	0.000123	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6R—hematologic cancer	6.64e-06	0.000123	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—hematologic cancer	6.63e-06	0.000123	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CREBBP—hematologic cancer	6.63e-06	0.000123	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCG2—hematologic cancer	6.61e-06	0.000122	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTR—hematologic cancer	6.61e-06	0.000122	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FN1—hematologic cancer	6.55e-06	0.000121	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—hematologic cancer	6.48e-06	0.00012	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO2—hematologic cancer	6.48e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BAD—hematologic cancer	6.47e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKBIA—hematologic cancer	6.47e-06	0.00012	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH1—hematologic cancer	6.41e-06	0.000119	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2RA—hematologic cancer	6.36e-06	0.000118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAP2K1—hematologic cancer	6.33e-06	0.000117	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—hematologic cancer	6.31e-06	0.000117	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—hematologic cancer	6.29e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CD—hematologic cancer	6.29e-06	0.000116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—hematologic cancer	6.29e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CD80—hematologic cancer	6.28e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—hematologic cancer	6.27e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KIT—hematologic cancer	6.27e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—NRAS—hematologic cancer	6.27e-06	0.000116	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—hematologic cancer	6.23e-06	0.000115	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTPN11—hematologic cancer	6.16e-06	0.000114	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—hematologic cancer	6.15e-06	0.000114	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SDC1—hematologic cancer	6.14e-06	0.000114	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFB—hematologic cancer	6.14e-06	0.000113	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	6.1e-06	0.000113	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGF2—hematologic cancer	6.02e-06	0.000111	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CREBBP—hematologic cancer	6.01e-06	0.000111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK3—hematologic cancer	6e-06	0.000111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TSC2—hematologic cancer	6e-06	0.000111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CREB1—hematologic cancer	5.97e-06	0.00011	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3R1—hematologic cancer	5.94e-06	0.00011	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BRAF—hematologic cancer	5.89e-06	0.000109	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.89e-06	0.000109	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL2—hematologic cancer	5.84e-06	0.000108	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6R—hematologic cancer	5.82e-06	0.000108	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CREBBP—hematologic cancer	5.81e-06	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGFR3—hematologic cancer	5.77e-06	0.000107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JAK2—hematologic cancer	5.77e-06	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK14—hematologic cancer	5.71e-06	0.000106	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CD—hematologic cancer	5.7e-06	0.000105	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—hematologic cancer	5.65e-06	0.000105	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MDM2—hematologic cancer	5.63e-06	0.000104	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—hematologic cancer	5.62e-06	0.000104	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—hematologic cancer	5.61e-06	0.000104	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAP2K1—hematologic cancer	5.55e-06	0.000103	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FN1—hematologic cancer	5.54e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CD—hematologic cancer	5.51e-06	0.000102	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	5.51e-06	0.000102	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MTOR—hematologic cancer	5.48e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CB—hematologic cancer	5.48e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKBIA—hematologic cancer	5.47e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BAD—hematologic cancer	5.47e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—hematologic cancer	5.46e-06	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH1—hematologic cancer	5.42e-06	0.0001	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—hematologic cancer	5.4e-06	9.98e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3R1—hematologic cancer	5.38e-06	9.95e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD80—hematologic cancer	5.31e-06	9.82e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KIT—hematologic cancer	5.3e-06	9.8e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—hematologic cancer	5.3e-06	9.8e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—NRAS—hematologic cancer	5.3e-06	9.8e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF2—hematologic cancer	5.28e-06	9.76e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—hematologic cancer	5.23e-06	9.67e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NQO1—hematologic cancer	5.22e-06	9.66e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CD44—hematologic cancer	5.22e-06	9.66e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTPN11—hematologic cancer	5.21e-06	9.63e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3R1—hematologic cancer	5.2e-06	9.62e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1B—hematologic cancer	5.14e-06	9.51e-05	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—hematologic cancer	5.09e-06	9.4e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK3—hematologic cancer	5.07e-06	9.38e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JAK2—hematologic cancer	5.06e-06	9.35e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CREB1—hematologic cancer	5.04e-06	9.33e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—hematologic cancer	5.04e-06	9.32e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—hematologic cancer	5.03e-06	9.3e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—hematologic cancer	5.01e-06	9.26e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BRAF—hematologic cancer	4.98e-06	9.21e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CB—hematologic cancer	4.97e-06	9.18e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—hematologic cancer	4.96e-06	9.17e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYCS—hematologic cancer	4.94e-06	9.14e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MDM2—hematologic cancer	4.94e-06	9.13e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL2—hematologic cancer	4.94e-06	9.12e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6R—hematologic cancer	4.92e-06	9.1e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CREBBP—hematologic cancer	4.91e-06	9.08e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HSP90AA1—hematologic cancer	4.91e-06	9.08e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—hematologic cancer	4.91e-06	9.07e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUN—hematologic cancer	4.89e-06	9.05e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MTOR—hematologic cancer	4.8e-06	8.88e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CB—hematologic cancer	4.8e-06	8.88e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—hematologic cancer	4.75e-06	8.77e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—hematologic cancer	4.73e-06	8.75e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAP2K1—hematologic cancer	4.69e-06	8.67e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CD—hematologic cancer	4.66e-06	8.61e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK8—hematologic cancer	4.63e-06	8.56e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—hematologic cancer	4.62e-06	8.54e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.61e-06	8.53e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—hematologic cancer	4.59e-06	8.48e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—hematologic cancer	4.56e-06	8.43e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EP300—hematologic cancer	4.52e-06	8.35e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1B—hematologic cancer	4.51e-06	8.34e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF2—hematologic cancer	4.46e-06	8.25e-05	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—hematologic cancer	4.46e-06	8.25e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—hematologic cancer	4.42e-06	8.17e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—hematologic cancer	4.41e-06	8.16e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3R1—hematologic cancer	4.4e-06	8.13e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SRC—hematologic cancer	4.39e-06	8.12e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—hematologic cancer	4.39e-06	8.12e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—hematologic cancer	4.36e-06	8.06e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—hematologic cancer	4.3e-06	7.95e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUN—hematologic cancer	4.29e-06	7.94e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—hematologic cancer	4.29e-06	7.93e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—hematologic cancer	4.28e-06	7.91e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAK2—hematologic cancer	4.28e-06	7.9e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—hematologic cancer	4.23e-06	7.83e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NRAS—hematologic cancer	4.22e-06	7.81e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—hematologic cancer	4.19e-06	7.75e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MDM2—hematologic cancer	4.17e-06	7.72e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—hematologic cancer	4.16e-06	7.69e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—hematologic cancer	4.15e-06	7.68e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—EP300—hematologic cancer	4.09e-06	7.57e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK8—hematologic cancer	4.06e-06	7.51e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CB—hematologic cancer	4.06e-06	7.51e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MTOR—hematologic cancer	4.06e-06	7.51e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—hematologic cancer	4.05e-06	7.49e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK3—hematologic cancer	4.05e-06	7.48e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOR1—hematologic cancer	4e-06	7.4e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—hematologic cancer	4e-06	7.4e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EP300—hematologic cancer	3.96e-06	7.32e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—hematologic cancer	3.93e-06	7.27e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—hematologic cancer	3.93e-06	7.26e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—hematologic cancer	3.88e-06	7.17e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SRC—hematologic cancer	3.85e-06	7.12e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1B—hematologic cancer	3.81e-06	7.05e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—hematologic cancer	3.77e-06	6.97e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—hematologic cancer	3.75e-06	6.93e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—hematologic cancer	3.73e-06	6.9e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—hematologic cancer	3.73e-06	6.89e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—hematologic cancer	3.71e-06	6.86e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—hematologic cancer	3.71e-06	6.86e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NRAS—hematologic cancer	3.7e-06	6.85e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—hematologic cancer	3.64e-06	6.72e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—hematologic cancer	3.64e-06	6.72e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUN—hematologic cancer	3.63e-06	6.71e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK3—hematologic cancer	3.55e-06	6.56e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—hematologic cancer	3.54e-06	6.54e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—hematologic cancer	3.52e-06	6.5e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—hematologic cancer	3.51e-06	6.49e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—hematologic cancer	3.45e-06	6.38e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—hematologic cancer	3.44e-06	6.36e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK8—hematologic cancer	3.43e-06	6.35e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—hematologic cancer	3.42e-06	6.33e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EP300—hematologic cancer	3.35e-06	6.19e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—hematologic cancer	3.34e-06	6.18e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SRC—hematologic cancer	3.25e-06	6.02e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—hematologic cancer	3.23e-06	5.97e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—hematologic cancer	3.19e-06	5.89e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—hematologic cancer	3.17e-06	5.86e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—hematologic cancer	3.14e-06	5.8e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NRAS—hematologic cancer	3.13e-06	5.79e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—hematologic cancer	3.09e-06	5.71e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—hematologic cancer	3.03e-06	5.6e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK3—hematologic cancer	3e-06	5.54e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.97e-06	5.5e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—hematologic cancer	2.96e-06	5.47e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—hematologic cancer	2.93e-06	5.41e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—hematologic cancer	2.92e-06	5.39e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—hematologic cancer	2.91e-06	5.38e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—hematologic cancer	2.83e-06	5.24e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CREBBP—hematologic cancer	2.76e-06	5.1e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—hematologic cancer	2.73e-06	5.04e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—hematologic cancer	2.71e-06	5.01e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—hematologic cancer	2.69e-06	4.98e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.61e-06	4.83e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—hematologic cancer	2.59e-06	4.79e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—hematologic cancer	2.58e-06	4.77e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—hematologic cancer	2.48e-06	4.58e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—hematologic cancer	2.47e-06	4.57e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3R1—hematologic cancer	2.47e-06	4.56e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—hematologic cancer	2.39e-06	4.43e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—hematologic cancer	2.39e-06	4.42e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—hematologic cancer	2.29e-06	4.23e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.28e-06	4.21e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—hematologic cancer	2.19e-06	4.05e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—hematologic cancer	2.02e-06	3.74e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—hematologic cancer	1.97e-06	3.64e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—EP300—hematologic cancer	1.88e-06	3.47e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.39e-06	2.57e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—hematologic cancer	1.13e-06	2.1e-05	CbGpPWpGaD
